DOCSLIB.ORG

Cutaneous T-Cell Lymphoma: Mycosis Fungoides/Se´Zary Syndrome: Part 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cutaneous T-Cell Lymphoma: Mycosis Fungoides/Se´Zary Syndrome: Part 1 FEATURE ARTICLE Cutaneous T-Cell Lymphoma: Mycosis Fungoides/Se´zary Syndrome: Part 1 Susan Booher, MS, RN, Sue Ann McCann, MSN, RN, DNC, Marianne C. Tawa, RN, MSN, ANP INTRODUCTION (Lutzner et al., 1975). The term CTCL should not be used Cutaneous T-cell lymphoma (CTCL) represents a category interchangeably with MF and SS; rather, it should be used of complex and diverse disease states that involve the skin only to describe the complete spectrum of cutaneous lym- as the primary site of malignant T-lymphocyte proliferation phomas of T-cell origin. and is a type of non-Hodgkin lymphoma. These malignant The World Health Organization and the European CD4+ T cells (lymphocytes) also can invade the lymphatic Organisation for Research and Treatment of Cancer met nodes, blood, and visceral organs. Mycosis fungoides (MF) in 2003 and 2004 to organize and define the cutaneous and its leukemic variant, Se´zary syndrome (SS), are the lymphomas and to separate them from systemic lymphomas most common types of CTCL. These chronic diseases are with similar histology (Willemze et al., 2005). Lymphomas rare and have considerable variation in cutaneous presen- are now classified as either T-cell or B-cell lymphoma with tation, histologic appearance, degree of blood involvement, indolent, intermediate, or aggressive clinical behavior, al- immunophenotypic profile, and prognosis. lowing for more consistent diagnosis and treatment regi- Historically, the French were pioneers in the discovery of mens (see Figure 4-1). CTCL. Approximately 200 years ago, Jean Louise Alibert published an article describing the appearance of tumors on EPIDEMIOLOGY the skin similar to that of a mushroom and coined the term MF and SS are rare diseases despite evidence that their mycosis fungoides (Alibert, 1806). In 1938, French phy- prevalence is increasing. Utilizing the National Cancer sicians Se´zary and Bouvrain published the discovery of an Institute_s Surveillance, Epidemiology, and End Results atypical T lymphocyte in the blood of a patient who had data, Criscione and Weinstock (2007) reported that the skin findings that were consistent with MF and who was incidence of CTCL tripled to 6.4 per million from 1973 to erythrodermic at the same time. Further advances in cuta- 2002 in the United States, with a 2.9-per-million increase neous lymphomas continued in the 20th century with the per decade over the same period. This increased incidence discoveries of cutaneous B-cell, natural killer cell, and may be a result of better medical awareness and screening gamma delta-cell lymphomas, as well as variants of MF. methods. CTCL occurs 32% more often in blacks than In the mid-1970s, Edelson and Lutzner coined the term in whites, and the ratio of male to female is 2:1 with CTCL to unify all the diagnoses recognized as cancer that an increase in incidence with age. CTCL in children is shared a common T-cell phenotype including MF and SS confirmed but uncommon. MF was found to be respon- sible for 72% of all CTCL cases, and SS represented 2.5% of all CTCLs. Overall, CTCL represents 3.9% of all non- Reprinted with permission by the Oncology Nursing Society from Site Hodgkin lymphomas, with substantial geographic varia- Specific Cancer Series: Skin Cancer. Muehlbauer, P & McGowan, C(Eds).Chap4:pp81Y93. Copyright 2009, Oncology Nursing tion in incidence. An increased incidence is found in areas Society. Part 2 will appear in the March/April issue of the Journal of with high physician density, high family income, higher the Dermatology Nurses’ Association. education, and high home property values. These findings DOI: 10.1097/JDN.0b013e31820a3e82 may represent a difference in access to medical care and, 18 Journal of the Dermatology Nurses’ Association Copyright @ 2011 Dermatology Nurses' Association. Unauthorized reproduction of this article is prohibited. The pathology of MF and SS is characterized by neo- plastic CD4+ T cells that preferentially home to migrate and expand in the skin. CD4+ T cells help to regulate the generation of T-cellYmediated responses, which are func- tionally mediated by another class of T cells that express the surface protein CD8+. Generally, the malignant T cells in MF and SS show signs of activation, releasing cytokines and other proteins that cause the skin cells (keratinocytes) to proliferate, leading to scaling and thickening of the epidermis characteristic of these diseases. These cytokines, including interleukin (IL)-4, may contribute to the mild- to-moderate immunosuppression that may be present in patients with MF and SS. Moreover, the release of cyto- kines may contribute to the pruritus that is present in many patients at all stages of MF and SS. In the patch and plaque stages of the disease, malignant T cells represent a relatively small proportion of total T cells in the skin because normal T cells, including those of the CD8+ phe- notype, often are present as a Breaction[ to the malignant T cells. When patients develop thick plaques and tumors, the majority of the T cells in these lesions are derived from the malignant clone (Girardi, Heald, & Wilson, 2004). Hwang et al. (2008) proposed that multiple abnormali- ties in the immune environment in the skin, including the antigen-presenting cells (also known as dendritic cells) that stimulate T cells, contribute to the clinical signs and FIGURE 4-1. World Health Organization/European Organi- symptoms of MF and SS. sation for Research and Treatment of Cancer Classifica- Malignant CD4+ MF and Se´zary cells generally ex- tion. Note. Based on information from Willemze et al., 2005. press the CD45RO surface protein marker, which identi- fies these cells as Bmemory[ T cells that have previously been activated by antigen. This marker differentiates these thus, earlier or better diagnosis. Nurses should be alert cells from CD45RA+ T cells that are BnaBve[ and have to the potential for opportunities for patient/community not yet been stimulated to proliferate by antigen. Memory education about CTCL. Given the evidence of an in- T cells have an enhanced ability to proliferate and to creasing incidence of CTCL, dermatology and oncology secrete cytokines, even in the presence of small amounts nurses must remain apprised of the latest literature on of antigen presented by antigen-presenting cells. Memory accurate detection and treatment of CTCL. T cells are proficient at migrating from the blood to in- flamed tissue, including skin, because they express specific chemotactic receptors known as chemokine receptors PATHOPHYSIOLOGY and adhesion molecules (Sallusto, Lenig, Forster, Lipp, The cause of MF and SS (as well as other CTCLs) is un- & Lanzavecchia, 1999). Evidence exists that CD45RO+ known. Infectious agents, including bacteria and viruses, tumor cells in patients with MF may escape immune re- have been proposed as possible triggers for CTCL cognition and destruction through expression of pro- (Hwang, Janik, Jaffe, & Wilson, 2008). Herne, Talpur, teins that potentially induce apoptosis of antitumor, Breuer-McHam, Champlin, and Duvic (2003) associated cytotoxic CD8+ T cells, which may otherwise control the cytomegalovirus infection with CTCL, and Chang, Liu, malignant T cells (Ni, Hazarika, Zhang, Talpur, & Duvic, Chen, and Chow (1998) detected the Epstein-Barr virus 2001). in patients with T-cell lymphomas of the skin. Although Alterations in specific cytokines and chemokines (small these associations are intriguing, the data are not strong chemotactic proteins) have been proposed to contribute enough to conclude that a causal relation exists. How- to clonal expansion and immunosuppression in MF and ever, the quest to find the etiology of MF and SS has led SS (Yamanaka et al., 2006b). IL-18 expression may play to a great increase in information available about the a role in the immunosuppression that is characteristic of genetic and immune abnormalities found in MF and SS. late-stage CTCL (Yamanaka et al., 2006a). IL-15, which Ultimately, understanding the pathophysiology of MF requires presentation by antigen-presenting cells, may con- and SS may help in the development of novel therapies to tribute to T-cell proliferation (Dooms et al., 1998). IL-4 treat these lymphoid malignancies (Hwang et al.). and IL-5, which skew the immune environment, can lead VOLUME 3 | NUMBER 1 | JANUARY/FEBRUARY 2011 19 Copyright @ 2011 Dermatology Nurses' Association. Unauthorized reproduction of this article is prohibited. toward a humoral (antibody-mediated) Th2-type immune contribute to the immunosuppression seen in MF, particu- response (Vowels et al., 1994). Additionally, chemokines larly in the late stages, or in SS. Therapies that target these may play a role in attracting malignant T cells to the abnormalities are beginning to show positive benefits in skin and enhancing their ability to survive by acting upon the treatment of MF and SS. G-proteinYcoupled chemokine receptors found on the sur- face of T cells (Clark et al., 2006; Notohamiprodjo et al., STAGING 2005; Sokolowska-Wojdylo et al., 2005). The most common staging system in use for CTCL was Edelson (2001) hypothesized that the survival and created in 1978 at a National Cancer Institute Workshop proliferation of the neoplastic T cells in MF and SS were on CTCL (Lamberg & Bunn, 1979). Subsequently, the enhanced by antigen-presenting dendritic cells based on International Society for Cutaneous Lymphoma updated evidence that dendritic cells support the long-term cul- the criteria for blood involvement to distinguish among ture of SS cells. Interestingly, skin dendritic cells known three subsets of erythrodermic CTCL (E-CTCL). The as Langerhans cells frequently localize in the epidermis subsets include SS as leukemic phase E-CTCL, erythro- adjacent to malignant T cells in MF, creating the so- dermic MF as secondary E-CTCL, and E-CTCL as not called Pautrier abscess, an often-observed histologic sign otherwise defined (Vonderheid et al., 2002). The leuke- of MF (see Figure 4-2).
Load more

Recommended publications
  • Comorbidities in Mycosis Fungoides and Racial Differences In
    medicines Article Comorbidities in Mycosis Fungoides and Racial Differences in Co-Existent Lymphomatoid Papulosis: A Cross-Sectional Study of 580 Patients in an Urban Tertiary Care Center Subuhi Kaul 1,*, Micah Belzberg 2, John-Douglas Matthew Hughes 3, Varun Mahadevan 2 , Raveena Khanna 2, Pegah R. Bakhshi 2, Michael S. Hong 2, Kyle A. Williams 2, 2 2, 2, Annie L. Grossberg , Shawn G. Kwatra y and Ronald J. Sweren y 1 Department of Medicine, John H. Stroger Hospital of Cook County, Chicago, IL 60612, USA 2 Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; [email protected] (M.B.); [email protected] (V.M.); [email protected] (R.K.); [email protected] (P.R.B.); [email protected] (M.S.H.); [email protected] (K.A.W.); [email protected] (A.L.G.); [email protected] (S.G.K.); [email protected] (R.J.S.) 3 Section of Dermatology, University of Calgary, Alberta, AB T2N 1N4, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-312-864-7000 Considered co-senior authors. y Received: 26 October 2019; Accepted: 24 December 2019; Published: 26 December 2019 Abstract: Background: Mycosis fungoides (MF) is a cutaneous T-cell lymphoma. Previous reports have suggested MF is associated with inflammatory conditions such as psoriasis, increased cardiovascular risk factors as well as secondary neoplasms. Methods: A cross-sectional study of MF patients seen from 2013 to 2019 was performed. Comorbidities were selected based on the 2015 Medicare report highlighting the most common chronic medical illnesses in the United States.
    [Show full text]
  • Rush University Medical Center, May 2005
    TABLE OF CONTENTS Case # Title Page 1. Malignant Spitz’s Nevus 1 2. Giant Congenital Nevus 4 3. Methotrexate Nodulosis 7 4. Apthae with Trisomy 8–positive Myelodysplastic Syndrome 10 5. Kwashiorkor 13 6. “Unknown” 16 7. Gangrenous Cellulitis 17 8. Parry-Romberg Syndrome 21 9. Wegener’s Granulomatosis 24 10. Pediatric CTCL 27 11. Hypopigmented Mycosis Fungoides 30 12. Fabry’s Disease 33 13. Cicatricial Alopecia, Unclassified 37 14. Mastocytoma 40 15. Cutaneous Piloleiomyomas 42 16. Granular Cell Tumor 44 17. Disseminated Blastomycoses 46 18. Neonatal Lupus 49 19. Multiple Lipomas 52 20. Acroangiodermatitis of Mali 54 21. Pigmented Basal Cell Carcinoma (BCC) 57 Page 1 Case #1 CHICAGO DERMATOLOGICAL SOCIETY RUSH UNIVERSITY MEDICAL CENTER CHICAGO, ILLINOIS MAY 18, 2005 CASE PRESENTED BY: Michael D. Tharp, M.D. Lady Dy, M.D., and Darrell W. Gonzales, M.D. History: This 2 year-old white female presented with a one year history of an expanding lesion on her left cheek. There was no history of preceding trauma. The review of systems was normal. Initially the lesion was thought to be a pyogenic granuloma and treated with two courses of pulse dye laser. After no response to treatment, a shave biopsy was performed. Because the histopathology was interpreted as an atypical melanocytic proliferation with Spitzoid features, a conservative, but complete excision with margins was performed. The pathology of this excision was interpreted as malignant melanoma measuring 4.0 mm in thickness. A sentinel lymph node biopsy was subsequently performed and demonstrated focal spindle cells within the subcapsular sinus of a left preauricular lymph node.
    [Show full text]
  • Utility of CD123 Immunohistochemistry in Differentiating Lupus Erythematosus from Cutaneous T-Cell Lymphoma
    DR PAUL WILLIAM HARMS (Orcid ID : 0000-0002-0802-2883) DR MAY P. CHAN (Orcid ID : 0000-0002-0650-1266) Article type : Original Article Utility of CD123 immunohistochemistry in differentiating lupus erythematosus from cutaneous T-cell lymphoma (Running title: CD123 in lupus and cutaneous T-cell lymphoma) Stephanie J. T. Chen1,2, Julie Y. Tse3, Paul W. Harms1,4, Alexandra C. Hristov1,4, May P. Chan1,4 1Department of Pathology, University of Michigan, Ann Arbor, MI 2Department of Pathology, University of Iowa, Iowa City, IA 3Department of Pathology, Tufts Medical Center, Boston, MA 4Department of Dermatology, University of Michigan, Ann Arbor, MI Corresponding author: May P. Chan, MD University of Michigan Author Manuscript NCRC Building 35 This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/HIS.13817 This article is protected by copyright. All rights reserved 2800 Plymouth Road Ann Arbor, MI 48109 Phone: (734)764-4460 Fax: (734)764-4690 Email: [email protected] The authors report no conflict of interest. Abstract: 250 words Manuscript: 2496 words Figures: 3 Tables: 2 Abstract Aims: Histopathologic overlap between lupus erythematosus and certain types of cutaneous T- cell lymphoma (CTCL) is well documented. CD123+ plasmacytoid dendritic cells (PDCs) are typically increased in lupus erythematosus, but have not been well studied in CTCL. We aimed to compare CD123 immunostaining and histopathologic features in these conditions.
    [Show full text]
  • Evaluation of Melanocyte Loss in Mycosis Fungoides Using SOX10 Immunohistochemistry
    Article Evaluation of Melanocyte Loss in Mycosis Fungoides Using SOX10 Immunohistochemistry Cynthia Reyes Barron and Bruce R. Smoller * Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA; [email protected] * Correspondence: [email protected] Abstract: Mycosis fungoides (MF) is a subtype of primary cutaneous T-cell lymphoma (CTCL) with an indolent course that rarely progresses. Histologically, the lesions display a superficial lymphocytic infiltrate with epidermotropism of neoplastic T-cells. Hypopigmented MF is a rare variant that presents with hypopigmented lesions and is more likely to affect young patients. The etiology of the hypopigmentation is unclear. The aim of this study was to assess melanocyte loss in MF through immunohistochemistry (IHC) with SOX10. Twenty cases were evaluated, including seven of the hypopigmented subtype. The neoplastic epidermotropic infiltrate consisted predominantly of CD4+ T-cells in 65% of cases; CD8+ T-cells were present in moderate to abundant numbers in most cases. SOX10 IHC showed a decrease or focal complete loss of melanocytes in 50% of the cases. The predominant neoplastic cell type (CD4+/CD8+), age, race, gender, histologic features, and reported clinical pigmentation of the lesions were not predictive of melanocyte loss. A significant loss of melanocytes was observed in 43% of hypopigmented cases and 54% of conventional cases. Additional studies will increase our understanding of the relationship between observed pigmentation and the loss of melanocytes in MF. Citation: Barron, C.R.; Smoller, B.R. Evaluation of Melanocyte Loss in Keywords: mycosis fungoides; hypopigmented mycosis fungoides; SOX10; cutaneous T-cell lymphoma Mycosis Fungoides Using SOX10 Immunohistochemistry.
    [Show full text]
  • Granulomatous Mycosis Fungoides, a Rare Subtype of Cutaneous T-Cell Lymphoma
    CASE REPORT Granulomatous mycosis fungoides, a rare subtype of cutaneous T-cell lymphoma Marta Kogut, MD,a Eva Hadaschik, MD,a Stephan Grabbe, MD,b Mindaugas Andrulis, MD,c Alexander Enk, MD,a and Wolfgang Hartschuh, MDa Heidelberg and Mainz, Germany Key words: Granulomatous dermatitis; granulomatous mycosis fungoides; T-cell receptor gamma gene. ranulomatous mycosis fungoides (GMF) is an unusual histologic subtype of cutaneous Abbreviations used: T-cell lymphoma.1 The diagnosis of GMF is GMF: granulomatous mycosis fungoides G INF-a: interferon alfa usually established after observation of a granulo- MF: mycosis fungoides matous inflammatory reaction associated with a TCR: T-cell receptor malignant lymphoid infiltrate. Epidermotropism, a clue to diagnosis in classical mycosis fungoides (MF) 2 may be absent in about 47% of cases of GMF. In ear, Mycobacterium gordonae grew in a culture; some instances, the granulomatous component may however, polymerase chain reaction results were be intense and obscures the lymphomatous compo- negative. The etiologic relevance was considered nent of the infiltrate.1 There are no distinctive clinical 1,3 questionable, and the appropriate systemic antibi- patterns associated with GMF. otic therapy did not show any effects. The histopathologic evaluation of biopsy speci- CASE REPORT mens from the ear and forearm found a lympho- In 1998 a 28 year-old male patient presented with histiocytic, lichenoid inflammatory infiltrate with desquamating erythema on his left auricle (Fig 1, A). epitheloid giant cell granulomas (Fig 3, A and B). On exam he also had erythematous scaly plaques on On the basis of the clinical findings of a chronic his forearms and trunk associated with surrounding ulceration and histologic evidence of granulomas, we alopecia (Fig 2, A).
    [Show full text]
  • Histologic Findings in Cutaneous Lupus Erythematosus 299
    CHAPTER 21 Histologic Findings in Cutaneous Lupus 21 Erythematosus Christian A. Sander, Amir S. Yazdi, Michael J. Flaig, Peter Kind Lupus erythematosus (LE) is a chronic inflammatory disease that can be clinically divided into three major categories: chronic cutaneous LE (CCLE), subacute cuta- neous LE (SCLE), and systemic LE (SLE). In general, LE represents a spectrum of dis- ease with some overlap of these categories. Classification is based on clinical, histo- logic, serologic, and immunofluorescent (see Chap. 22) features. Consequently, histologic findings alone may not be sufficient for correct classification. In addition, these categories can be subdivided into numerous variants affecting different levels of the skin and subcutaneous tissue. Chronic Cutaneous Lupus Erythematosus Discoid Lupus Erythematosus Discoid LE (DLE) is the most common form of LE. Clinically, the head and neck region is affected in most cases. On the face, there may be a butterfly distribution. However, in some cases, the trunk and upper extremities can be also involved. Lesions consist of erythematous scaly patches and plaques. Histologically, in DLE the epidermis and dermis are affected, and the subcuta- neous tissue is usually spared. However, patchy infiltrates may be present. Character- istic microscopic features are hyperkeratosis with follicular plugging, thinning, and flattening of the epithelium and hydropic degeneration of the basal layer (liquefac- tion degeneration) (Fig. 21.1). In addition, there are scattered apoptotic keratinocytes (Civatte bodies) in the basal layer or in the epithelium. Particularly in older lesions, thickening of the basement membrane becomes obvious in the periodic acid-Schiff stain. In the dermis, there is a lichenoid or patchy lymphocytic infiltrate with accen- tuation of the pilosebaceous follicles.
    [Show full text]
  • Erythema Annulare Centrifugum Associated with Mantle B-Cell Non-Hodgkin’S Lymphoma
    Letters to the Editor 319 Erythema Annulare Centrifugum Associated with Mantle B-cell Non-Hodgkin’s Lymphoma Marta Carlesimo1, Laura Fidanza1, Elena Mari1*, Guglielmo Pranteda1, Claudio Cacchi2, Barbara Veggia3, Maria Cristina Cox1 and Germana Camplone1 1UOC Dermatology, 2UOC Histopathology and 3UOC Haematolohy, II Unit University of Rome Sapienza Via di Grottarossa, 1039, IT-00189 Rome, Italy. *E-mail: [email protected] Accepted September 25, 2008. Sir, superficial type (Fig. 2). Previous investigations were Figurate erythemas are classified as erythema annulare normal, but as the lesions persisted further investi- centrifugum (EAC), erythema gyratum repens, erythema gations were carried out. Hepatic, pancreatic, renal migrans and necrolytic migratory erythema. Differential function and blood pictures were normal. The lymph diagnoses are mycosis fungoides, urticaria, granuloma nodes on the left side of his neck were approximately annulare and pseudolymphoma. 4.5 cm in diameter. EAC consists of recurrent and persistent erythematous A lymph node biopsy revealed a small B-cell non- eruptions or urticarial papules forming annular or serpen- Hodgkin’s lymphoma. The neoplastic cells were tiginous patterns with an advancing macular or raised positive for CD20/79a and cyclin d1. A bone marrow border and scaling on the inner aspect of the border. investigation showed scattered CD20/79a­positive EAC was first described by Darier in 1916, and classi­ lymphocytes. GeneScan analysis and heteroduplex on fied in 1978 by Ackerman into a superficial and a deep polyacrylamide gel analysis showed a monoclonal B type (1, 2). EAC can be associated with a wide variety lymphocyte population. of triggers including infections, food and drug ingestion, endocrinological conditions and as a paraneoplastic sign.
    [Show full text]
  • Mycosis Fungoides and Sézary Syndrome: an Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy
    cancers Review Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy Nuria García-Díaz 1 , Miguel Ángel Piris 2,† , Pablo Luis Ortiz-Romero 3,† and José Pedro Vaqué 1,*,† 1 Molecular Biology Department, Universidad de Cantabria—Instituto de Investigación Marqués de Valdecilla, IDIVAL, 39011 Santander, Spain; [email protected] 2 Department of Pathology, Fundación Jiménez Díaz, CIBERONC, 28040 Madrid, Spain; [email protected] 3 Department of Dermatology, Hospital 12 de Octubre, Institute i+12, CIBERONC, Medical School, University Complutense, 28041 Madrid, Spain; [email protected] * Correspondence: [email protected] † Same contribution. Simple Summary: In the last few years, the field of cutaneous T-cell lymphomas has experienced major advances. In the context of an active translational and clinical research field, next-generation sequencing data have boosted our understanding of the main molecular mechanisms that govern the biology of these entities, thus enabling the development of novel tools for diagnosis and specific therapy. Here, we focus on mycosis fungoides and Sézary syndrome; we review essential aspects of their pathophysiology, provide a rational mechanistic interpretation of the genomic data, and discuss the current and upcoming therapies, including the potential crosstalk between genomic alterations Citation: García-Díaz, N.; Piris, M.Á.; and the microenvironment, offering opportunities for targeted therapies. Ortiz-Romero, P.L.; Vaqué, J.P. Mycosis Fungoides and Sézary Abstract: Primary cutaneous T-cell lymphomas (CTCLs) constitute a heterogeneous group of diseases Syndrome: An Integrative Review of that affect the skin. Mycosis fungoides (MF) and Sézary syndrome (SS) account for the majority the Pathophysiology, Molecular of these lesions and have recently been the focus of extensive translational research.
    [Show full text]
  • Identifi Cation of Herpes Simplex Virus DNA and Lack of Human
    214 Letters to the Editor Identi cation of Herpes Simplex Virus DNA and Lack of Human Herpesvirus-8 DNA in Mycosis Fungoides Emel Erkek1, Nilgu¨n Sentu¨rk1, Irem Dinc¸er2, Ali Ilgõ n Olut2, Tanõ l Kocago¨z2, Gu¨l Bu¨ku¨lmez1 and Sedef Sahin1 Departments of 1Dermatology and 2Clinical Microbiology; Hacettepe University Faculty of Medicine, Neyzen Tev k sokak, Ferah apt., 12/12 Maltepe, TR-06570 Ankara, Turkey. E-mail: [email protected] Accepted February 22, 2002. 2a-1) 5¢ CTG GTC AGC TTT CGG TAC GA 3¢ , and (HSV Sir, gB 2a-2) 5¢ CAG GTC GTG CAG CTG GTT GC 3¢ . These Human herpesvirus 8 (HHV-8) is the most recent putat- primers have been amplifying both types of HSV, namely ive human herpesvirus. Evidence was obtained using types I and II. As a positive control specimen, cerebrospinal molecular biology techniques (1). Speci c DNA uid of a patient with a clinical and serologically proven HSV sequences were rst identi ed in 1994 by Chang et al. encephalitis was used. (2) in Kaposi’s sarcoma tissues from patients with AIDS using the representational diVerence analysis technique. In the vast majority of cases, HHV-8 DNA sequences RESULTS AND DISCUSSION can be shown by polymerase chain reaction (PCR) in Using PCR, we were able to amplify DNA speci c for classical, endemic, iatrogenic and AIDS-associated HSV from 16 of 50 MF patients (32%). Thirteen out of Kaposi’s sarcoma (1). HHV-8 is also lymphotrophic 16 HSV-positive samples were diagnosed as MF eryth- and has the ability to immortalize cells (3, 4).
    [Show full text]
  • A Patient's Guide to Understanding Cutaneous Lymphoma
    WELCOME! If you or someone close to you has been given a diagnosis of cutaneous lymphoma, you probably have many questions and concerns. Living with cutaneous lymphoma and the many changes that this diagnosis brings to your life can leave you feeling overwhelmed, confused and lonely. You may not even be sure about what kinds of questions to ask. This guide was created so you can find valuable information to help you understand the disease, learn about available treatments and how to find specialists, access support, and ways to live the best life you can with cutaneous lymphoma. The Cutaneous Lymphoma Foundation is dedicated to providing patients, caregivers and loved ones with programs and services designed to help, support and provide hope to people who are given a diagnosis of cutaneous lymphoma. We are here for you. You are not alone. You are part of a knowledgeable, caring, resourceful, and compassionate community, and we’re here to help you. Get in touch anytime. We hope to hear from you or meet you in person at one of our patient events. We wish you all the best in your journey. The Staff and Board of Directors of the Cutaneous Lymphoma Foundation A Patient’s Guide to Understanding Cutaneous Lymphoma ACKNOWLEDGMENTS This guide is an educational resource published by the Cutaneous Lymphoma The Cutaneous Lymphoma Foundation acknowledges and thanks the Foundation providing general information on cutaneous lymphoma. Publication individuals listed below who have given generously of their time and expertise. of this information is not intended to take the place of medical care or the advice We thank them for their contributions, editorial wisdom and advice, which have of your physician(s).
    [Show full text]
  • FROM ACNE to RETINOIDS and LYMPHOMAS Composed by Anders Vahlquist, Editor-In-Chief
    ISSN 0001-5555 Volume 92 2012 No. 3 Theme Section A Non-profit International Journal for Skin Research, Clinical Dermatology and Sexually Transmitted Diseases Official Journal of - The International Forum for the Study of Itch - European Society for Dermatology and Psychiatry THEME ISSUE: FROM ACNE TO RETINOIDS AND LYMPHOMAS COMPOSED BY ANDERS VAHLQUIST, Editor-IN-CHIEF Acta Dermato-Venereologica www.medicaljournals.se/adv Acta Derm Venereol 2012; 92: 227–289 THEME ISSUE: FROM ACNE TO RETINOIDS AND LYMPHOMAS Composed by Anders Vahlquist, Editor-in-Chief This theme issue of Acta Dermato-Venereologica bridges two bexarotene exert positive and negative effects far beyond seemingly unrelated diseases, acne and lymphoma, by inclu- those of pure RAR agonists. For the former drug, this is il- ding papers on retinoid therapy for both conditions. Beginning lustrated in a large trial on chronic hand eczema (p. 251) and with acne vulgaris, accumulating evidence suggests that diet in a pilot study of its use for congenital ichthyosis (p. 256). after all plays a role, which is ventilated in a commentary (p. For bexarotene, a new Finnish study shows 10 years expe- 228) of a prospective study using low- and high-calorie diets rience of this therapy in severe cutaneous lymphoma (p. 258). in adolescents with acne (p. 241). Acne treatment regimes Depending on the stage of the disease, lymphomas can also usually differ from one country to another; a Korean survey be treated for instance with photodynamic therapy (p. 264) (p. 236) combined with a review on how to treat post-acne and methotrexate (p. 276).
    [Show full text]
  • R&D Pipeline
    R&D Pipeline antibody protein small molecule ◎ New Molecular Entity Updated since Dec. 31, 2020 Updated since Dec. 31, 2020 Nephrology As of Mar. 31, 2021 Code Name Stage [In-House or Licensed] Generic Name Mechanism of Action Indication Area Remarks Formulation PhⅠ PhⅡ PhⅢ Filed Approved KHK7580 CN [Mitsubishi Tanabe Pharma] Evocalcet Calcimimetic Secondary Hyperparathyroidism Asia product name in Japan: Orkedia Oral Diabetic Kidney Disease JP ◎RTA 402 Antioxidant Inflammation Bardoxolone Methyl [Reata] Modulator Oral Autosomal Dominant Polycystic JP Kidney Disease KW-3357 Recombinant Human [In-House] Antithrombin Gamma Preeclampsia JP Antithrombin product name in Japan:Acoalan Injection KHK7791 Hyperphosphatemia Under Tenapanor NHE3 Inhibitor JP [Ardelyx] Maintenance Dialysis Oral Oncology Code Name Stage [In-House or Licensed] Generic Name Mechanism of Action Indication Area Remarks Formulation PhⅠ PhⅡ PhⅢ Filed Approved AU CH [In-House] KW-0761 Anti-CCR4 Humanized Mycosis Fungoides and SA POTELLIGENT® Mogamulizumab Antibody Sézary Syndrome KR product name in Japan, U.S. and Injection Europe: Poteligeo CA KW ◎KHK2375 Entinostat HDAC Inhibitor Breast Cancer JP [Syndax] Oral Mobilization of Hematopoietic Stem Cells into Peripheral Blood JP for Allogeneic Blood Stem Cell KRN125 Long-Acting Transplantation [Kirin-Amgen] Pegfilgrastim Granulocyte Colony- product name in Japan:G-Lasta Injection Stimulating Factor Automated Injection Device for Decreasing the Incidence of JP Febrile Neutropenia in Patients Receiving Cancer Chemotherapy [In-House]
    [Show full text]